期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Doxorubicin: The dogma and the bone
1
作者 jia y.wong Pornsak Sriamornsak Crispin R.Dass 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2016年第1期22-23,共2页
Doxorubicin is an anthracycline drug used as frontline chemotherapy of osteosarcoma among other types of cancers.While quite effective in providing a good control over the tumours in some patients,it can cause signifi... Doxorubicin is an anthracycline drug used as frontline chemotherapy of osteosarcoma among other types of cancers.While quite effective in providing a good control over the tumours in some patients,it can cause significant toxicity to organs such as the heart[1].Attempts to ameliorate this toxicity with agents such as dexrazoxane have been successful,but not without complications[2]as will be discussed in this talk.Pigment epithelium-derived factor(PEDF),a potent antiangiogenic and osteogenetic protein[3],was used to reduce this side-effect,together with an analysis of levels of adenosine triphosphate(ATP)and reactive oxygen species(ROS).The effects of low dose doxorubicin in a clinically relevant dosing model will be discussed. 展开更多
关键词 DOXORUBICIN Cancer TUMOUR APOPTOSIS CARDIOTOXICITY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部